Tag: peripheral arterial disease

CX 2024: Paclitaxel device restrictions “did cause harm”

“Unfortunately, we are doing worse for our patients today,” were the sobering words of Eric Sece...

TCT 2023: First presentation of complete patient-level dataset on paclitaxel and death that helped sway the US FDA

Data from a patient-level meta-analysis—a factor in the US Food and Drug Administration’s (FDA) ...

SCAI welcomes FDA decision to remove red flag for use of paclitaxel-coated devices in PAD

The president of the Society for Cardiovascular Angiography & Interventions (SCAI), George D...

Boston Scientific announces position on FDA update about use of paclitaxel-coated devices to treat PAD

Following yesterday's news that the US Food and Drug Administration (FDA) has changed its stance on ...

Long-awaited US FDA update finds data do not support excess mortality risk for paclitaxel-coated devices

In a letter to healthcare providers dated 11 July 2023, the US Food and Drug Administration (FDA...

Black patients nearly 50% less likely to receive revascularisation for PAD

A new study from Keck Medicine at the University of Southern California (USC; Los Angeles, USA) ...

BASIL-2 points towards endovascular-first revascularisation strategy in CLTI patients

A question from Manj Gohel (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK) on w...

AVS’s pulsatile IVL technology attracts an additional US$8.8 million to close US$28.8 million Series B round

AVS, an early-stage medical device company focused on safely and effectively treating severely c...
VOYAGER

New VOYAGER PAD analysis confirms consistent benefit of low-dose rivaroxaban plus aspirin following lower extremity revascularisation

Data from a new prespecified analysis of the phase III VOYAGER PAD clinical trial show that low-...
IVL

Cardiovascular Systems announces development of IVL technology for the treatment of coronary and peripheral arterial diseases

Cardiovascular Systems recently announced that it has made significant progress towards the commerci...

VIVA 2021: Consensus established for appropriate use of IVUS in peripheral interventions

A worldwide committee of 40 cross-specialty medical experts achieved the first-ever consensus fo...

ACC 2021: VOYAGER-PAD analysis shows totality of ischaemic events reduced following rivaroxaban use

Rupert Bauersachs (Darmstadt, Germany) talks to Cardiovascular News about the VOYAGER-PAD trial,...

New guideline: ASA no longer recommended to prevent first stroke, heart disease

A new Heart & Stroke guideline published today in the Canadian Medical Association Journal does ...

Positive NICE recommendation for Xarelto to prevent atherothrombotic events in CAD and PAD patients

The National Institute for Health and Care Excellence (NICE) has published the final appraisal deter...

Two-year MAJESTIC data show sustained positive results for Eluvia drug-eluting stent

The MAJESTIC trial set out to evaluate the performance of the Eluvia paclitaxel-eluting vascular ste...